ProfoundBio is a clinical-stage biotechnology company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer. Built on internally developed, innovative, and proprietary technology platforms, ProfoundBio has developed a pipeline consisting of multiple antibody-drug conjugate (ADC) drug candidates targeting solid tumors and hematological malignancies that are in discovery, preclinical, and clinical development stages. The Company’s clinical stage programs are rinatabart sesutecan (Rina-S; PRO1184), an ADC targeting folate receptor alpha, PRO1160, an ADC targeting CD70, and PRO1107, an ADC targeting PTK7. ProfoundBio is headquartered in Seattle, WA, USA.

Xianfeng Qiyun

Gaorong Capital

K2VC

Chang'an Capital

Oriza Holdings

Sequoia Capital China

Lilly Asia Ventures

LYFE Capital

Surveyor Capital

T. Rowe Price

Ally Bridge Group

Piper Heartland Healthcare Capital

Janus Henderson Investors

LifeSci Venture Partners

Logos Capital

Medicxi

ProfoundBio

Are you going to be at #AACR2024 in San Diego? Don’t miss ProfoundBio’s presentations from our novel #ADC pipeline. Read more: https://lnkd.in/ga2ffDfq. #cancerresearch #biotech

Proud to share that ProfoundBio has secured $112 million in an oversubscribed Series B round, fueling our mission to advance novel cancer treatments, including advancing our flagship #ADC, rinatabart sesutecan (Rina-S) into late-stage clinical development. Deep gratitude to our esteemed life science investors for backing our vision. A big welcome to Andrew Lam, PharmD, Eric Dobmeier, and Enoch Kariuki, PharmD for joining our Board of Directors. With their guidance, we're diving deep into the next phase of innovation in #cancerresearch Learn more: https://lnkd.in/djG5g9EM 

#AntibodyDrugConjugates #Oncology #TargetedTherapy #SeriesBFinancing #BiotechInnovation

ProfoundBio is thrilled to announce the initiation of dosing in the Phase 1/2 clinical trial of PRO1107, marking a significant step forward in our efforts to develop antibody-drug conjugates (ADCs) with improved clinical outcomes for cancer patients. PRO1107 is a pioneering Protein Tyrosine Kinase 7 (PTK7)-targeted ADC that leverages our novel, proprietary hydrophilic MMAE-based linker-drug, aiming to set new standards in safety and efficacy for MMAE-based ADCs in the fight against cancer.

A heartfelt thank you to our dedicated investigators and the patients participating in this trailblazing research. Your involvement is pivotal in driving forward our mission to deliver groundbreaking treatments.

Read more: https://lnkd.in/gKXsEwsB

#ProfoundBio #ClinicalTrial #CancerResearch #InnovationInOncology #BiotechLinkedIn

📣 ProfoundBio is thrilled to announce that rinatabart sesutecan (Rina-S) has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA)!

See our press release for more info 👉 : https://lnkd.in/gx9MUXiJ

Developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others

Regeneron Pharmaceuticals

Specializes in biology-guided radiotherapy for treating all stages of cancer

RefleXion Medical

Focused on developing cancer therapies using a proprietary protein degradation platform

Aro Biotherapeutics

Develops personalized T cell immunotherapies for treating cancer

Tmunity Therapeutics

Oncology-focused biotech company developing novel therapeutics for cancer treatment

Avstera Therapeutics

ProfoundBio is a biotechnology company that specializes in the development of novel therapeutics aimed at treating various forms of cancer. The company leverages its proprietary technology platform to identify and advance new cancer therapies through the drug development pipeline.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	May 7, 2024 7:23 PM	bc04f74f
public peers	general	May 7, 2024 7:23 PM	c590afc2
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	May 7, 2024 7:23 PM	22bccfd9
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	May 7, 2024 7:23 PM	536ed2c7
translate crunchbase fundingrounds	general
peers	general
news basic	general	May 7, 2024 7:23 PM	ce5228ff
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:PROFOUNDBIO

ProfoundBio